In a groundbreaking move, Nevro Corp. has released a consensus statement endorsed by the Worldwide Initiative for Diabetes Education, supporting the use of high-frequency (10 kHz) Spinal Cord Stimulation (SCS) for refractory Pain in Diabetic Neuropathy (PDN). Experts in diabetes, pain management, and health services have come together to champion this innovative therapy, particularly emphasizing Nevro’s HFX system.
Global Recognition for High-Frequency SCS
The consensus statement, featured in Diabetes Research and Clinical Practice, underscores the efficacy of high-frequency SCS in addressing PDN symptoms that prove resistant to initial treatments. A panel of interdisciplinary experts, convened at the WorldWIDE Diabetes Virtual Global Summit in December 2022, collaborated on this groundbreaking declaration. High-frequency SCS therapy, notably Nevro’s HFX, is recommended for PDN symptoms that remain unresponsive to first- and second-line therapies. The global consensus reinforces the imperative role of SCS therapy, particularly highlighting Nevro’s HFX, in managing refractory PDN symptoms.
Dr. David Caraway, Chief Medical Officer at Nevro, emphasized the pivotal role of findings from the SENZA-PDN RCT (Randomized Controlled Trial), the most extensive RCT evaluating SCS for PDN. The study’s outcomes have significantly contributed to validating high-frequency (10 kHz) SCS as an effective treatment for this challenging patient population. The SENZA-PDN experiment demonstrated the efficacy of high-frequency SCS in alleviating difficult PDN symptoms.
Positive Outcomes from SENZA-PDN RCT
Dr. Erika Petersen, the lead primary investigator for SENZA-PDN and a neurosurgery professor, highlighted the improvements observed during the experiment. High-frequency SCS not only provided pain relief but also positively impacted quality of life, sleep patterns, and neurological function in PDN patients. The findings from the study suggest that high-frequency SCS holds promise in enhancing overall outcomes for individuals struggling with PDN.
Nevro’s 10 kHz Therapy™: A Global Standard
Pain in Diabetic Neuropathy affects approximately 50% of individuals with type 2 diabetes, significantly impacting their quality of life. Traditional oral painkillers often prove ineffective and come with unacceptable adverse effects, leading to a myriad of additional challenges for PDN patients, including sleep disturbances, sadness, and anxiety.
Nevro’s 10 kHz Therapy™ stands out as the only FDA-approved high-frequency paresthesia-free SCS system designed to address Pain in Diabetic Neuropathy. The consensus statement not only reaffirms the pain-reducing capabilities of Nevro’s unique technology but also acknowledges its potential in restoring neurological function for PDN patients. This recognition from global experts serves as a testament to Nevro’s unwavering commitment to developing innovative chronic pain treatment solutions.
Read More:
- Indicted for Attempted Murder: Controversial Decision Raises Questions About Mental Health and Legal System
- Ohio’s Erica Stefanko Faces Life Sentence in Retrial for 2012 Pizza Delivery Murder Case
- Tennessee’s Proposed Parental Accountability Act Raises Concerns in Memphis
In addition to the consensus statement, prestigious organizations such as the American Diabetes Association, German Diabetes Association, and American Association of Clinical Endocrinologists have all endorsed high-frequency SCS as a viable and endorsed treatment option for Pain in Diabetic Neuropathy. The widespread support further solidifies Nevro’s position at the forefront of advancing chronic pain management solutions globally.